Pipeline overview
Evexta Bio is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
Rupitasertib
Unique dual S6K AKT1/3 inhibitor
In-licensed from Merck KGaA
ER+ HER2- Breast Cancer
| Combination with SERD
ER+ HER2- Breast Cancer
| Combination with CDK4/6i
HER2+ Breast Cancer
| Combination with trastuzumab
Glioblastoma multiforme
| Combination with radiotherapy
Gastric Cancer
| Combination with SOC
EVX-020
Sole-in-class KIF20A Inhibitor
Proprietary program
Hematologic Malignancies
| Payload for ADC
Solid Tumors
| Payload for ADC